DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/twb8wh/lebrikizumab) has announced the addition of the "Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Roche's lebrikizumab is under development for the treatment of patients with moderate to severe asthma who respond poorly to medium or high doses of ICSs. Lebrikizumab is a first-in-class immunoglobulin G4 (IgG4) humanized mAb that specifically binds to and inhibits the activity of IL-13. IL-13 is a pleiotropic cytokine of the Th2 cell response that contributes to asthma pathogenesis via increased chemokine secretion and mucus hyperexcretion, increased cholinergic-induced contractions, and smooth muscle proliferation (Khurana Hershey, 2003). Clinical studies have correlated the presence of elevated periostin levels with the increased efficacy of lebrikizumab.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lebrikizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lebrikizumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/twb8wh/lebrikizumab